Clinical Research Directory

Inclusion Criteria: 1. Endoscopy shows bilateral nasal polyps, with bilateral NPS ≥4 (≥2 per side) 2. Nasal obstruction symptoms \>3 months, nasal obstruction score ≥2 (total 3 points) and/or hyposmia ≥2 (maximum 3 points) 3. Evidence of type 2 inflammation: Nasal polyp tissue Eos \>55/HPF or \>27% of inflammatory cells; or Peripheral blood Eos ≥6.9% (without asthma) or ≥3.7% (with asthma) Note: Meet any 2 of the above 3 criteria 4. Failure after 4 weeks of standard medical therapy including: Intranasal corticosteroids \>4 weeks; Other agents (oral steroids, macrolides, antihistamines, leukotriene receptor antagonists, decongestants, antibiotics) permitted as needed Exclusion Criteria: 1. Cystic fibrosis, Young's syndrome, Kartagener syndrome, antrochoanal polyp, or rhinitis medicamentosa 2. Acute upper respiratory infection within 2 weeks 3. Asthma exacerbation within 1 month 4. HIV infection 5. Parasitic infection within 6 months 6. History of hypersensitivity to investigational drugs (except aspirin intolerance) 7. Hypersensitivity to monoclonal antibodies or anti-IL-5 agents 8. Oral steroid therapy within 1 month 9. Pregnancy planning, current pregnancy, or lactation 10. Uncontrolled systemic diseases 11. Have a history of previous sinus surgery for CRSwNP 12. Significant septal deviation affecting unilateral ventilation (mild deviation allowed) 13. Investigator judgment of unsuitability for cohort study